Drug Approval | March 25, 2022
Japan approves BMS’ Breyanzi application for relapsed large B-cell lymphoma
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The test can overcome the time and cost limitations of traditional culture-based drug susceptibility testing as it can more rapidly detect all mutations known to be associated with drug resistance for any TB drug in one step
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
It is the fourth vaccine to get the nod for 12 years and older after Biological E’s Corbevax, Bharat Biotech’s Covaxin and Zydus Lifesciences Zy-CoV-D
Data to establish the safety profile and human dose of vaccine candidate
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Prof. Kypros has revolutionised the field of fetal medicine through his extensive research and medical practice achievements, including introducing intrauterine blood transfusions for fetal anaemia
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
Subscribe To Our Newsletter & Stay Updated
